Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Torti

Showing results (191-200 of 241) with videos related to

Pageof 25
Sort By:
Blood|September 26, 2008
Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelatorYan Jiao, John Wilkinson, Xiumin Di, et al.
Cancer Research|November 29, 2013
IRP2 regulates breast tumor growthWei Wang, Zhiyong Deng, Heather Hatcher, et al.
Circulation. Cardiovascular Imaging|July 13, 2010
Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental modelJames C Lightfoot, Ralph B D'Agostino, Craig A Hamilton, et al.
Journal of Medicinal Chemistry|December 13, 2005
N-picolyl derivatives of Kemp's triamine as potential antitumor agents: a preliminary investigationCeleste Aida S Regino, Suzy V Torti, Rong Ma, et al.
Carcinogenesis|September 29, 2001
p53-independent apoptosis mediated by tachpyridine, an anti-cancer iron chelatorR D Abeysinghe, B T Greene, R Haynes, et al.
Biomaterials|January 17, 2012
The resistance of breast cancer stem cells to conventional hyperthermia and their sensitivity to nanoparticle-mediated photothermal therapyAndrew R Burke, Ravi N Singh, David L Carroll, et al.
Annals of Internal Medicine|December 1, 1983
Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsyF M Torti, M R Bristow, A E Howes, et al.
Cancer Chemotherapy and Pharmacology|June 15, 2007
A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinomaWalter M Stadler, Apurva A Desai, David I Quinn, et al.
Cancer Research|July 5, 2019
Stearoyl-CoA Desaturase 1 Protects Ovarian Cancer Cells from Ferroptotic Cell DeathLia Tesfay, Bibbin T Paul, Anna Konstorum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2004
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583)Eric J Small, Susan Halabi, Nancy A Dawson, et al.
Pageof 25

Showing results (191-200 of 241) with videos related to

Sort By:
Pageof 25
Blood|September 26, 2008
Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelatorYan Jiao, John Wilkinson, Xiumin Di, et al.
Cancer Research|November 29, 2013
IRP2 regulates breast tumor growthWei Wang, Zhiyong Deng, Heather Hatcher, et al.
Circulation. Cardiovascular Imaging|July 13, 2010
Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental modelJames C Lightfoot, Ralph B D'Agostino, Craig A Hamilton, et al.
Journal of Medicinal Chemistry|December 13, 2005
N-picolyl derivatives of Kemp's triamine as potential antitumor agents: a preliminary investigationCeleste Aida S Regino, Suzy V Torti, Rong Ma, et al.
Carcinogenesis|September 29, 2001
p53-independent apoptosis mediated by tachpyridine, an anti-cancer iron chelatorR D Abeysinghe, B T Greene, R Haynes, et al.
Biomaterials|January 17, 2012
The resistance of breast cancer stem cells to conventional hyperthermia and their sensitivity to nanoparticle-mediated photothermal therapyAndrew R Burke, Ravi N Singh, David L Carroll, et al.
Annals of Internal Medicine|December 1, 1983
Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsyF M Torti, M R Bristow, A E Howes, et al.
Cancer Chemotherapy and Pharmacology|June 15, 2007
A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinomaWalter M Stadler, Apurva A Desai, David I Quinn, et al.
Cancer Research|July 5, 2019
Stearoyl-CoA Desaturase 1 Protects Ovarian Cancer Cells from Ferroptotic Cell DeathLia Tesfay, Bibbin T Paul, Anna Konstorum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2004
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583)Eric J Small, Susan Halabi, Nancy A Dawson, et al.
Pageof 25